Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSWNJF)

Drug Name
Ravulizumab Drug Info
Synonyms Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210
Indication
Disease Entry ICD 11 Status REF
Paroxysmal nocturnal haemoglobinuria 3A21.0 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMSWNJF

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [1]
HUMAN complement C5 protein (C5) TTN0GJ5 CO5_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Paroxysmal nocturnal haemoglobinuria
ICD Disease Classification 3A21.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 ClinicalTrials.gov (NCT04369469) Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia. U.S. National Institutes of Health.
3 Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23.